| 06th week of 2012 patent applcation highlights part 43 |
| Patent application number | Title | Published |
|---|
| 20120035057 | ROOM-TEMPERATURE SUPERCONDUCTIVE-LIKE DIODE DEVICE - Methods and apparatus characterized by distinct operating modes are provided. A thin graphite material defined by graphene layers is supported on a silicon substrate. The graphite material is defined by edge sites at the interface with the silicon. The graphite material is characterized by electrical superconductive-like behavior at room-temperatures while electrical current flows there through in a first direction. The graphite material is further characterized by a transition to Ohmic behavior while electrical current flows there through in a second direction opposite to the first. Devices exhibiting diode-like behavior can be formed accordingly. | 2012-02-09 |
| 20120035058 | COIL NODE VOLTAGE OUTPUTS FOR SUPERCONDUCTING MAGNETS - In a superconducting magnet assembly a plurality of superconducting coils, joined in series, are housed within a cryostat. A coil node between two electrically adjacent of the superconducting coils provides an input voltage. A coil node voltage output is provided comprising a series resistor connected between the coil node and a further node. A non-linear element is connected between the further node and a ground voltage, and an output connector is electrically connected to the further node and traverses a boundary of the cryostat. | 2012-02-09 |
| 20120035059 | Metal Assembly Constituting A Precursor For A Superconductor, A Superconductor And A Method Suitable For The Production Of A Superconductor - The invention relates to an assembly ( | 2012-02-09 |
| 20120035060 | HIGHLY MULTIPLEXED GENOTYPING USING LEUKOREDUCED BLOOD SAMPLES - Described herein are methods and kits useful for the extraction and analysis of genomic DNA from leukoreduced blood or plasma samples. | 2012-02-09 |
| 20120035061 | OPTICAL IMAGING BASED ON VISCOELASTIC FOCUSING - An apparatus arranged for examining particles, comprising: a cartridge having at least one microchannel, a viscoelastic fluid flowing in the microchannel, the fluid comprising a suspension of particles, thereby effecting alignment of the particles in at least one-dimensional array parallel to the fluid flow, and an optical magnifying means generating an image of the particles in the microchannel. | 2012-02-09 |
| 20120035062 | ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS - A method for sequencing a polynucleotide strand by using sequencing-by-synthesis techniques. To address the problem of incomplete extension (IE) and/or carry forward (CF) errors that can occur in sequencing-by-synthesis reactions, an alternative flow ordering of dNTPs is used. In contrast to conventional flow orderings, the dNTPs are flowed in an ordering that is not a continuous repeat of an ordering of the four different dNTPs. This alternate flow ordering may reduce the loss of phasic synchrony in the population of template polynucleotide strands that result from IE and/or CF errors. | 2012-02-09 |
| 20120035063 | Use of Chemically Patterned Substrate for Liquid Handling, Chemical and Biological Reactions - Methods and devices for adding liquids to and washing a microfluidic element array are disclosed. The method and devices feature a microfluidic plate holder with a sloped wall for improved draining of liquid, a machine readable/writable identifier, plate leveling systems, liquid filling systems, a hydrophilic-liquid coating, and an automated washing station. | 2012-02-09 |
| 20120035064 | POLYMORPH, POLYMORPH SCREENING SYSTEM, AND POLYMORPH PREPARING AND SCREENING METHOD - A polymorph, a polymorph screening system, and a polymorph preparing and screening method are disclosed. The polymorph preparing and screening method includes the following steps: providing a plurality of substrates of different materials; causing an organic material to grow crystals on the plurality of substrates through solution-cooling crystallization process, so that a plurality of polymorphs with different characteristics are prepared; and screening the plurality of polymorphs prepared in the previous step to obtain polymorphs with desired characteristics. | 2012-02-09 |
| 20120035065 | Aptamer Regulated Nucleic Acids and Uses Thereof - The invention relates to aptamer-regulated, ligand-responsive nucleic acids, or “ampliSwitches,” and uses thereof. Particular embodiments include a ligand-responsive nucleic acid that comprises a primer sequence domain and an aptamer domain that is responsive to a ligand. | 2012-02-09 |
| 20120035066 | CONJUGATED POLYMERS FOR USE IN HOMOGENEOUS AND SOLID STATE ASSAYS - The invention further relates to multichromophores, which may be conjugated polymers, and methods, articles and compositions employing them as described herein. In some aspects, the invention relates to methods, articles and compositions for the detection and analysis of biomolecules in a sample. Provided assays include those determining the presence of a target biomolecule in a sample or its relative amount, or the assays may be quantitative or semi-quantitative. The methods can be performed on a substrate. The methods can be performed in an array format on a substrate, which can be a sensor. In some embodiments, detection assays are provided employing sensor biomolecules that do not comprise a fluorophore that can exchange energy with the cationic multichromophore. In some aspects biological assays are provided in which energy is transferred between one or more of the multichromophore, a label on the target biomolecule, a label on the sensor biomolecule, and/or a fluorescent dye specific for a polynucleotide, in all permutations. The multichromophore may interact at least in part electrostatically with the sensor and/or the target, and an increase in energy transfer with the polymer may occur upon binding of the sensor and the target. Other variations of the inventions are described further herein. | 2012-02-09 |
| 20120035067 | Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation - The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression. | 2012-02-09 |
| 20120035068 | USE OF MIRCO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY - Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound. | 2012-02-09 |
| 20120035069 | PROGNOSIS OF BREAST CANCER PATIENTS BY MONITORING THE EXPRESSION OF TWO GENES - The present invention relates to the expression of two genes, CyclinG2 and Sharp1, which correlates with prognosis in individuals having breast cancer. Specifically, this invention provides a method to stratify samples from breast cancer patients in a high or low recurrence risk in the years following primary tumor removal. This classification can be achieved through the analysis of protein or mRNA expression levels for the two identified genes. The invention also illustrates how CyclinG2 and Sharp1 have been identified in mammary cancer cell lines and validated in a large cohort of human patients as powerful metastasis predictors. | 2012-02-09 |
| 20120035070 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF - There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1). | 2012-02-09 |
| 20120035071 | HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE PROBES AND PRIMERS FOR DETECTION OF MICROORGANISMS - Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes. | 2012-02-09 |
| 20120035072 | KASPP (LRRK2) GENE, ITS PRODUCTION AND USE FOR THE DETECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD. | 2012-02-09 |
| 20120035073 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2012-02-09 |
| 20120035074 | METHODS TO DETERMINE ATHEROSCLEROSIS REGRESSION, PLAQUE STABILIZTION AND CARDIOVASCULAR RISK - Provided herein are compositions and methods for examining the progression, regression or risk of individuals at risk for developing coronary artery disease (CAD). | 2012-02-09 |
| 20120035075 | CARTRIDGE FOR AN AMPLIFICATION PROCESS - The invention relates to real-time array PCR cartridges. The cartridge ( | 2012-02-09 |
| 20120035076 | IRAK KINASE FAMILY AS NOVEL TARGET AND BIOMARKER FOR ALZHEIMER - The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease. | 2012-02-09 |
| 20120035077 | Modified renilla luciferase nucleic acids and methods of use - This invention provides modified nucleotide sequences encoding luciferase that have greater expression than wild type luciferase. | 2012-02-09 |
| 20120035078 | ENGINEERING COMPLEX MICROBIAL PHENOTYPES WITH TRANSCRIPTION ENHANCEMENT - The present invention relates to a recombinant | 2012-02-09 |
| 20120035079 | GENOTOXICITY TESTING - The present invention relates to methods for detecting for the presence of an agent that putatively causes or potentiates DNA damage comprising subjecting a cell (containing a DNA sequence encoding | 2012-02-09 |
| 20120035080 | OPTICAL LENS SYSTEM AND METHOD FOR MICROFLUIDIC DEVICES - An apparatus for imaging one or more selected fluorescence indications from a microfluidic device. The apparatus includes an imaging path coupled to least one chamber in at least one microfluidic device. The imaging path provides for transmission of one or more fluorescent emission signals derived from one or more samples in the at least one chamber of the at least one microfluidic device. The chamber has a chamber size, the chamber size being characterized by an actual spatial dimension normal to the imaging path. The apparatus also includes an optical lens system coupled to the imaging path. The optical lens system is adapted to transmit the one or more fluorescent signals associated with the chamber. | 2012-02-09 |
| 20120035081 | NON-POLAR SOLID INKS FOR BIOMEDICAL APPLICATIONS - A microfluidic device includes a first substrate, and a phase change ink deposited on a surface of the first substrate. The phase change ink includes a non-polar polymeric material and an optional colorant, wherein the phase change ink is solid at room temperature but is liquid at a jetting temperature of from about 60 to about 150° C., and a water contact angle on the deposited phase change ink is from 90° to about 175°. | 2012-02-09 |
| 20120035082 | Synthesis of Oligomers in Arrays - Systems, including apparatus and methods, for synthesis of oligomers in arrays. | 2012-02-09 |
| 20120035083 | Antireflective Coatings for High-Resolution Photolithographic Synthesis of DNA Array - The present invention provides an array of polymers and methods of forming arrays of polymers by providing a substrate having a first layer including one or more dielectric coatings on a solid support and a second layer including a plurality of polymers disposed on the first layer. The invention also provides methods for forming an array of polymers on a substrate using light-directed synthesis by providing a substrate having a first layer including one or more dielectric coatings on a solid support, derivatizing the first layer by contacting the first layer with a silanation reagent, and a second layer disposed on said first layer wherein the second layer includes functional groups protected with a photolabile protecting group. | 2012-02-09 |
| 20120035084 | DEVICE AND METHOD FOR PARTICLE COMPLEX HANDLING - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 2012-02-09 |
| 20120035085 | DRAG-REDUCING COPOLYMER COMPOSITIONS - A method of preparing and using a drag-reducing composition in a well treatment operation includes the step of preparing the drag-reducing composition by mixing a polymer emulsion that includes a first surfactant and a first solvent, with a second surfactant and a second solvent. The method continues with the step of combining the drag-reducing composition with an aqueous treatment fluid. The method further includes the step of injecting the drag-reducing composition and aqueous treatment fluid into a subterranean formation, a pipeline or a gathering line. | 2012-02-09 |
| 20120035086 | Methods and Compositions for Inhibiting Metal Corrosion - Methods of inhibiting the corrosion of a metal surface contacted by an aqueous acid solution. The methods combine a corrosion inhibiting composition with the aqueous acid solution, wherein the corrosion inhibiting composition comprises a reaction product of an alpha,beta-unsaturated ketone with a primary or secondary amine. The metal surface is then contacted with the aqueous acid solution comprising the corrosion inhibiting composition, thereby inhibiting corrosion thereon. | 2012-02-09 |
| 20120035087 | Universal synthetic lubricant additive with micro lubrication technology to be used with synthetic or miner host lubricants from automotive, trucking, marine, heavy industry to turbines including, gas, jet and steam - It is known by the inventor that a universal synthetic lubricant additive that can greatly enhance the performance standards of existing lubricants, petroleum based or synthetic, imparts a new and desirable property not originally present in the existing oil or it reinforces a desirable property already possessed in some degree can greatly benefit the consumer. Although additives of many diverse types have been developed to meet special lubrication needs, their principal functions are relatively few in number. This universal synthetic lubricant additive (invention) with micro lubrication technology, when used as directed will reduce the oxidative or thermal degradation of the host oil, substantially reduce the deposition of harmful deposits in lubricated parts, minimize rust and corrosion, control frictional properties, reduce wear, temperature, sludge, varnishes and prevent destructive metal-to-metal contact, reduce fuel consumption and harmful emissions while improving performance through increased horsepower and torque. | 2012-02-09 |
| 20120035088 | LUBRICANT COMPOSITION HAVING IMPROVED ANTIWEAR PROPERTIES - The instant invention provides a lubricant composition having improved four-ball antiwear properties. The lubricant composition includes a base oil and one or more alkylethercarboxylic acid corrosion inhibitor(s) having the formula: | 2012-02-09 |
| 20120035089 | REMOVAL OF BACTERIAL ENDOTOXINS - Methods of cleaning a medical device are provided via exposing the medical device to a compressed CO | 2012-02-09 |
| 20120035090 | Isosorbide Monoesters And Their Use In Household Applications - Isosorbide monoesters according to the general formula (I) wherein R′ or R″ represent a hydrogen atom, or an group CO—R′″, with the proviso that one group R′ or R″ is a hydrogen atom, and R′″ represents linear or branched, saturated or unsaturated alkyl- or alkenyl groups with 6 to 22 C-atoms are useful compounds in the preparation of all kind of detergents, in particular dish washing detergents or of cosmetic preparations. | 2012-02-09 |
| 20120035091 | Aqueous Highly Acidic Hard Surface Cleaning Compositions - Provided are highly aqueous liquid acidic hard surface cleaning composition having a pH of about 3 or less which comprise: an acid constituent, preferably comprising sulfamic acid and preferably at least one or more further co-acids, and preferably wherein the acid constituent comprises both sulfamic acid and formic acid; at least one nonionic surfactant based on monobranched alkoxylated C10/C11-fatty alcohols; an organic solvent constituent which comprises at least one glycol ether solvent, preferably a glycol ether solvent which desirably mitigates or masks malodors of the acid constituent, especially when the acid constituent comprises formic acid; optionally a cosurfactant constituent, including one or more nonionic, cationic, amphoteric or zwitterionic surfactants; optionally one or more further constituents selected coloring agents, fragrances and fragrance solubilizers, viscosity modifying agents including one or more thickeners, pH adjusting agents and pH buffers including organic and inorganic salts, optical brighteners, opacifying agents, hydrotropes, abrasives, and preservatives, as well as other optional constituents known to the art; and the balance, water, wherein water comprises at least 80% wt. of the composition. | 2012-02-09 |
| 20120035092 | LIQUID CLEANING COMPOSITIONS WITH FILMS - A cleaning composition that contains film flakes with beneficial ingredients. The composition with the film flakes releases the beneficial ingredients when it is delivered to the target surface. | 2012-02-09 |
| 20120035093 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof - Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided. | 2012-02-09 |
| 20120035094 | F11 RECEPTOR (F11R) ANTAGONISTS AS THERAPEUTIC AGENTS - The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal. | 2012-02-09 |
| 20120035095 | ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY - This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose. | 2012-02-09 |
| 20120035096 | AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION - There is provided an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of arteriosclerosis, which have excellent safety, improve functions associated with the vascular endothelium, have effects of preventing various diseases associated with vascular endothelial functions and of inhibiting vascular intimal thickening, and may be expected to provide prophylactic effect on arteriosclerosis or the like. The agents of the present invention contain, as an active component: (a) Xaa-Pro-Pro, (b) a hydrolysate of animal milk casein containing Xaa-Pro-Pro, or a concentrate thereof, or (c) a fermentation product containing Ile-Pro-Pro and/or Val-Pro-Pro obtained by fermenting a starting material containing milk protein with a bacterial strain of the species | 2012-02-09 |
| 20120035097 | METHODS OF TREATING BACTERIAL INFECTIONS USING ORITAVANCIN - The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range. | 2012-02-09 |
| 20120035098 | NOVEL ANTIVIRAL AGENT - The present invention describes the use of a composition including or constituted by at least one element chosen from:
| 2012-02-09 |
| 20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 2012-02-09 |
| 20120035100 | SATIATION PEPTIDE ADMINISTRATION - Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY. | 2012-02-09 |
| 20120035101 | LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME - Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed. | 2012-02-09 |
| 20120035102 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF - Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention. | 2012-02-09 |
| 20120035103 | METHOD FOR ADMINISTRATION OF INSULIN AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention provides pharmaceutical compositions including alkylglycosides admixed with at least one of fast-acting and long-acting insulin analogs for treatment of disorders, such as diabetes. | 2012-02-09 |
| 20120035104 | Insulin derivatives - The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds. | 2012-02-09 |
| 20120035105 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments - The present invention includes a pharmaceutical composition comprising HDV insulin or oral HDV insulin, and one or more additional therapeutic agents useful for the treatment of diabetes and diabetes related ailments. The present invention also includes a method of making the pharmaceutical inventions of the application. The present invention further includes methods of treating diabetes and/or diabetes related ailments comprising administering a pharmaceutical composition of the invention to a patient in need thereof. The present invention also includes methods of treating diabetes related ailments comprising administering a pharmaceutical formulation of HDV insulin or a pharmaceutical formulation of oral HDV insulin. | 2012-02-09 |
| 20120035106 | USE OF APL-TYPE PEPTIDE FOR TREATING INTESTINAL INFLAMMATORY DISEASES AND TYPE 1 DIABETES - The present invention is related with the field of the medicine, particularly with the use of an APL peptide or its analogues derived from the human heat shock protein of 60 kDa, for the manufacture of a pharmaceutical composition for the treatment of Crohn's disease, ulcerative colitis and diabetes mellitus type 1. This peptide is biodistributed into the gastrointestinal tract and also promotes the induction of apoptosis in activated intestinal lamina propria and peripheral blood T cells of patients with Crohn's disease. Furthermore, this peptide induces apoptosis in mononuclear cells of patients with diabetes mellitus type 1. | 2012-02-09 |
| 20120035107 | COMPOSITIONS FOR ACHIEVING A THERAPEUTIC EFFECT IN AN ANATOMICAL STRUCTURE - Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect. | 2012-02-09 |
| 20120035108 | SPRAY BASE MATERIAL INCLUDING LOW-MOLECULAR GELATOR - There is provided a spray base material that can be safely used with a sense of security, that prevents leakage of liquid from a spray container, that is sprayable under any condition (when inverted, for example), that is sprayable to achieve uniform coating of the surface of an object (surface to be sprayed) without scattering, that causes no dripping from a sprayed surface, and that is safe when sprayed on a skin surface and the like; and a spray base material with an excellent sprayability that can include both hydrophilic and hydrophobic low-molecular compounds such as physiologically active compounds and perfume components to be used in pharmaceuticals, agrochemicals, and cosmetics, and that has a sustained release property. A spray base material comprising an aqueous medium that is gelled by a low-molecular gelator in the medium, wherein the low-molecular gelator includes one, two, or more compounds selected from a group consisting of low-molecular compounds capable of gelling the aqueous medium via self-assembly. | 2012-02-09 |
| 20120035109 | FOLLICLE STIMULATING HORMONE SUPERAGONISTS - This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 2012-02-09 |
| 20120035110 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE - Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH | 2012-02-09 |
| 20120035111 | Therapeutic Application of Adiponectin in Patients with Acute Myocardial Infarction - A therapeutic method for cardiac diseases such as angina, myocardial infarction, arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation) is provided. The method is characterized by intracoronary administration of adiponection to mammals. | 2012-02-09 |
| 20120035112 | NEURONAL DIFFERENTIATION-INDUCING PEPTIDE AND USE THEREOF - A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide. | 2012-02-09 |
| 20120035113 | METHODS OF REDUCING TRAIL-INDUCED APOPTOSIS BY TRAIL ISOFORMS - This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided. | 2012-02-09 |
| 20120035114 | INHIBITORS OF STAT3 AND USES THEREOF - Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor. | 2012-02-09 |
| 20120035115 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION - The invention features compounds of formula I or II: | 2012-02-09 |
| 20120035116 | BILE ACIDS AND BIGUANIDES AS PROTEASE INHIBITORS FOR PRESERVING THE INTEGRITY OF PEPTIDES IN THE GUT - This invention relates to methods of preserving the integrity of peptides in the gut. In particular it concerns the use of certain compounds as inhibitors of gut proteases. Compounds identified as having gut protease inhibitory activity are biguanides, certain bile acids and pharmaceutically acceptable salts of these compounds. This activity makes these compounds useful for co-administration with prophylactic or therapeutic peptides. This invention relates to methods of inhibiting gut proteases and peptide formulations comprising these gut protease inhibitor. | 2012-02-09 |
| 20120035117 | Process for Synthesis of Cyclic Octapeptide - This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Cys(Trt)-2-Chlorotrityl resin is coupled with various amino acids to obtain a protected heptapeptide of formula (2): Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-2-Chlorotrityl resin. The linear protected peptide of formula (2) is cleaved from the support using TFA5TIS and water to yield linear protected peptide of formula (3) Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-OH Linear protected heptapeptide of formula (3) is deprotected to yield heptapeptide of formula (6): D-Phe-Cys-Phe-D-Tip-Lys-Thr-Cys-OH; which is cyclized using hydrogen peroxide and to the cyclic peptide of formula (7) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-OH; threoninol is coupled at C terminal to yield octreotide. Alternatively threoninol is coupled to the heptapeptide of formula (3) to yield protected octapeptide of formula (4) Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-Thr-OL which is subsequently deprotected to yield linear octapeptide of formula (5) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OL and cyclized with hydrogen peroxide to yield cyclic octreotide with a yield of >95%. | 2012-02-09 |
| 20120035118 | PHARMACEUTICAL COMBINATIONS - Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed. | 2012-02-09 |
| 20120035119 | Extracts and Compounds from Ficus Benghalensis for Increasing Hair Growth and Decreasing Hair Loss - This application discloses natural product extracts and compounds from an aerial root of a | 2012-02-09 |
| 20120035120 | GLYCOLIPIDS AS TREATMENT FOR DISEASE - This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy. | 2012-02-09 |
| 20120035121 | ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF - An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the C | 2012-02-09 |
| 20120035122 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS - This invention recites isoxazoline substituted azetidine derivatives of Formula (1) | 2012-02-09 |
| 20120035123 | COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES - A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described. | 2012-02-09 |
| 20120035124 | USE OF NIFURATEL TO TREAT INFECTIONS CAUSED BY ATOPOBIUM SPECIES - The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat' infections caused by | 2012-02-09 |
| 20120035125 | FULVIC ACID IN COMBINATION WITH FLUCONAZOLE OR AMPHOTERICIN B FOR THE TREATMENT OF FUNGAL INFECTIONS - A combination of fulvic acid or a salt, ester, or derivative thereof and an antifungal compound selected from fluconazole and amphotericin B for use in the treatment or prophylaxis of a disease or condition of the human or animal body is described. The fulvic acid can be CHD-FA. | 2012-02-09 |
| 20120035126 | Compounds For Reducing Drug Resistance And Uses Thereof - This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds. | 2012-02-09 |
| 20120035127 | PROCESS FOR THE PRODUCTION OF A COMPOSITION, THE COMPOSITION AND THE USE THEREOF AS FOOD ADDITIVE - The present invention relates to a process for the production of a functional food additive, such as a prebiotic composition, comprising the steps of. (a) providing a plant based material wherein the plant is selected from the group consisting of cereals, legumes, tubers and mixtures thereof, wherein said plant based material comprises dietary fiber optionally starchy material and optionally glucose, or wherein said plant based material comprises starchy material, and optionally glucose; (b): (b1) hydrolyzing or tranglucosylating at least part of the dietary fiber into glucose and into at least one non-digestible oligosaccharide and optionally into at least one non-digestible polysaccharide, and optionally hydrolyzing and transglucosylating at least part of the starchy material to glucose and into at least one non-digestible oligosaccharide, or, (b2) hydrolyzing and transglucosylating at least part of the starchy material to glucose and into at least one non-digestible oligosaccharide, and optionally hydrolyzing at least part of the maltooligosaccharides produced in step (b2) into glucose; (c) oxidizing at least part of the total glucose, consisting of at least part of said gluconic acid and/or a salt thereof obtained in step (c); thereby obtaining a composition comprising dietary fiber and gluconic acid or a salt thereof, wherein said dietary fiber comprises at least one non-digestible oligosaccharide and optionally at least one non-digestible polysaccharide as defined in claim | 2012-02-09 |
| 20120035128 | POLYSACCHARIDE DERIVATIVE AND HYDROGEL THEREOF - Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C | 2012-02-09 |
| 20120035129 | HYDROGEL TISSUE ADHESIVE HAVING REDUCED DEGRADATION TIME - A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery. | 2012-02-09 |
| 20120035130 | Chirally Correct Retinal Cyclodextrin Acetals for Clarifying Skin Complexion - The present invention discloses certain chirally correct polyene cyclodextrin acetals and hemiacetals (formula I) that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof; | 2012-02-09 |
| 20120035131 | PYRAZOLINE COMPOUNDS - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: | 2012-02-09 |
| 20120035132 | BORON-CONTAINING SMALL MOLECULES - Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed. | 2012-02-09 |
| 20120035133 | Lyophilization Cakes of Proteasome Inhibitors - Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use. | 2012-02-09 |
| 20120035134 | CHEMICAL COMPOUNDS - The present invention relates to compounds of Formula (I): | 2012-02-09 |
| 20120035135 | Treatment of Transgenic Crops with Mixtures of Fiproles and Chloronicotinyls - The Invention relates to methods for increasing the production potential of plants and/or controlling pests in plants with at least one transgenic modification related to yield increase as compared to a corresponding wild-type plant, comprising treating the location where the plant with at least one transgenic modification is growing or is expected to grow and/or the transgenic plant with at least one transgenic modification or propagation material of the plant with at least one transgenic modification with an effective amount of an insecticidal composition comprising a component A, selected from the group consisting of imidacloprid, thiacloprid, clothianidin, acetamiprid, dinotefuran, nitenpyram, and thiamethoxam; and a component B, selected from the group consisting of fipronil and ethiprole. | 2012-02-09 |
| 20120035136 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof. | 2012-02-09 |
| 20120035137 | USE OF INOSITOL-TRIPYROPHOSPHATE IN TREATING TUMORS AND DISEASES - Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis. | 2012-02-09 |
| 20120035138 | Bisphosphonate Formulation - A bisphosphonate is formulated with an agent to reduce surface tension and/or reduce foaming in the stomach, leading to reduced reflux and oesophageal irritation in use and increased patient compliance. | 2012-02-09 |
| 20120035139 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS - Gamma-amino-butyric acid derivatives that are GABA | 2012-02-09 |
| 20120035140 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF - The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP. | 2012-02-09 |
| 20120035141 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT - The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents. | 2012-02-09 |
| 20120035142 | POLYMORPHS OF DARUNAVIR - The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection. | 2012-02-09 |
| 20120035143 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS - The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. | 2012-02-09 |
| 20120035144 | MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID, AND AN ANTIFUNGAL AGENT, AND A PROCESS TO MAKE IT. - The present invention is directed to a medicinal composition for treating skin inflammations, fungal/bacterial skin infections and related wounds, and also other skin wounds including those caused by burns. The cream also causes skin rejuvenation through an epithelisation process. The cream comprises:
| 2012-02-09 |
| 20120035145 | METHODS OF TREATING MULTIPLE MYELOMA USING MELPHALAN, PREDNISONE AND LENALIDOMIDE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2012-02-09 |
| 20120035146 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE - Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks. | 2012-02-09 |
| 20120035147 | METHOD FOR TREATMENT OF DISEASES - The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal. | 2012-02-09 |
| 20120035148 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS - Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. | 2012-02-09 |
| 20120035149 | Prokineticin Receptor Antagonists And Uses Thereof - Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes. | 2012-02-09 |
| 20120035150 | MIF INHIBITORS AND THEIR USES - The invention relates to MIF inhibitors; compositions comprising an effective amount of a MIF inhibitor; and methods for treating or preventing diseases associated with MIF. | 2012-02-09 |
| 20120035151 | SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE - The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing. | 2012-02-09 |
| 20120035152 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS - The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R | 2012-02-09 |
| 20120035153 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS - The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R | 2012-02-09 |
| 20120035154 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 2012-02-09 |
| 20120035155 | INDOLE-2-CARBOXAMIDE DEIVATIVE - To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherein, R | 2012-02-09 |
| 20120035156 | COMBINATION OF GLYT1 COMPOUND WITH ANTIPSYCHOTICS - The present invention relates to a pharmaceutical combination of a glycine transporter inhibitor (GlyT1) and an atypical antipsychotic drug which may be used for the treatment of positive and negative symptoms of schizophrenia. | 2012-02-09 |
